February 2024 in “International Journal of Pharmaceutics” This study found that combining the natural product cedrol with minoxidil can improve the treatment of androgenetic alopecia by reducing the minoxidil dose needed, while a new nanocarrier system enhances drug delivery and effectiveness at hair follicles.
February 2024 in “Drug Delivery and Translational Research” In this study, a newly developed cardamonin-loaded liposomal formulation significantly enhanced hair growth and improved hair follicle performance in mice with androgenic alopecia.
October 2023 in “Bioactive Materials” This study developed a novel liposome-based delivery system for Minoxidil and nitric oxide, which showed promising results in promoting hair regrowth in an androgenetic alopecia model by enhancing transdermal absorption, prolonging skin retention, and reducing inflammation.
October 2023 in “International Journal of Pharmaceutics” This study found that ethosome-loaded minoxidil and tocopherol acetate improved hair regeneration and regulated the microenvironment around hair follicles better than commercial minoxidil in androgenic alopecia model mice, showing promise as a treatment strategy.
September 2023 in “Pharmaceuticals” This study found that nanoparticles containing minoxidil and betamethasone improved drug delivery to hair follicles, with lipidic nanoparticles significantly enhancing minoxidil and betamethasone penetration compared to control, making them a promising option for alopecia areata treatment with reduced side effects.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
February 2023 in “International Journal of Pharmaceutics” In this study, the researchers developed minoxidil cubosomes using nanotechnology, which improved drug penetration in the skin, showed greater hair growth efficacy, and reduced adverse skin reactions compared to traditional minoxidil solutions.
14 citations
,
May 2022 in “Asian Journal of Pharmaceutical Sciences” This review article highlights how hair follicle-targeting drug delivery systems enhance therapeutic outcomes and reduce side effects for treating conditions like androgenetic alopecia and acne vulgaris. The authors discuss current formulations and evaluate their performance in both preclinical and clinical settings.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
1 citations
,
August 2020 in “Journal of Cosmetic Dermatology” This study suggests that the novel "After Minoxidil" spray improved styling ease and reduced greasiness in patients using topical minoxidil, which may enhance compliance and treatment efficacy.
130 citations
,
August 2020 in “Drug Design Development and Therapy” This review discusses various nanoparticles used to enhance skin permeation and target delivery to skin organelles, but reports no new experimental results.
26 citations
,
February 2020 in “International Journal of Biological Macromolecules” This study demonstrates that massage significantly enhances the follicular targeting of dutasteride-loaded nanocapsules, increasing drug accumulation in hair follicles by up to 5 times.
26 citations
,
April 2019 in “Journal of Cosmetic Dermatology” This review discusses the potential of herbal treatments like Saw palmetto, Green tea, and Rosemary as alternatives to conventional drugs for androgenetic alopecia, noting that these herbs may inhibit the 5-alpha-reductase enzyme and reduce hair loss with fewer side effects.
32 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.
26 citations
,
August 2018 in “Dermatologic Therapy” This review discusses the research supporting the approval and use of minoxidil for androgenic alopecia and reports no new clinical results, emphasizing recent findings and developments.
33 citations
,
October 2016 in “European Journal of Pharmaceutical Sciences” This study found that a novel effervescent formulation significantly increased minoxidil sulphate accumulation in hair follicles and skin compared to a standard minoxidil solution.
110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
25 citations
,
July 2015 in “Colloids and Surfaces B: Biointerfaces” This study found that microencapsulation combined with iontophoresis can significantly enhance the delivery of minoxidil sulphate to hair follicles, suggesting a synergetic approach for topical drug targeting.
59 citations
,
May 2014 in “Expert Opinion on Therapeutic Targets” This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.
45 citations
,
August 2011 in “Journal of Microencapsulation” This study found that chitosan microparticles containing minoxidil sulphate sustained its release and may hold potential for targeted topical treatment of alopecia.
268 citations
,
April 2009 in “International Journal of Pharmaceutics” In this study, niosomal formulations enhanced minoxidil skin accumulation compared to commercial and control solutions, suggesting a potential improvement for topical delivery in hair loss treatment.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
47 citations
,
April 2003 in “Journal of dermatological science” This study showed that Thujae occidentalis semen extract inhibited 5alpha-reductase type 2 in laboratory tests and reduced androgen-related hair loss in animal models, suggesting potential use for male pattern baldness.
192 citations
,
March 1998 in “British Journal of Dermatology” This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.
166 citations
,
November 1990 in “Journal of Investigative Dermatology” Minoxidil sulfate stimulates hair growth.
38 citations
,
July 1989 in “Archives of dermatological research” Testosterone causes hair loss in AGA mice, which are good for testing baldness treatments, and both minoxidil and cyproterone acetate can prevent this hair loss.
